Syneos Health Inc
F:8IN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Valmont Industries Inc
NYSE:VMI
|
US |
Syneos Health Inc
Operating Income
Syneos Health Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Syneos Health Inc
F:8IN
|
Operating Income
$342.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Income
$8.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Operating Income
$5.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
9%
|
|
|
Waters Corp
NYSE:WAT
|
Operating Income
$800.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Income
$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Income
$2.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
Syneos Health Inc
Glance View
Syneos Health Inc., a formidable player in the biopharmaceutical realm, makes its mark as a dynamic integrated biopharmaceutical solutions organization. The company skillfully blends clinical development and commercial services to support pharma, biotech, and healthcare companies in navigating the complexities of bringing new therapies to market. With deep roots in clinical trials and commercialization, Syneos leverages its unique position of being involved in both the development and the market launch of new drugs—a dual focus that gives them a competitive advantage. Their business model thrives on partnerships, built on offering tailored solutions that bridge the gap between clinical insights and commercial acumen, allowing their clients to accelerate the journey from innovative ideas to patient impact. At the heart of Syneos Health's profitability are its two main segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions arm is committed to orchestrating the myriad stages of the drug development process, from early-phase trials to regulatory approval. This involves meticulously managing trials, patient recruitment, regulatory submissions, and data science applications to ensure efficacy and safety are satisfactorily demonstrated. Meanwhile, the Commercial Solutions division strategically steers approved products into the market with precision, leveraging an array of marketing, consulting, communications, and operations expertise. This holistic suite of services not only ensures a seamless transition from lab to market but also optimizes the commercial potential of their clients’ innovations, ensuring both regulatory and market success. Through these interwoven facets of clinical and commercial services, Syneos Health carves out a distinct role in the lifecycle of therapeutics development and delivery.
See Also
What is Syneos Health Inc's Operating Income?
Operating Income
342.8m
USD
Based on the financial report for Jun 30, 2023, Syneos Health Inc's Operating Income amounts to 342.8m USD.
What is Syneos Health Inc's Operating Income growth rate?
Operating Income CAGR 5Y
17%
Over the last year, the Operating Income growth was -27%. The average annual Operating Income growth rates for Syneos Health Inc have been 3% over the past three years , 17% over the past five years .